Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Thervet

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Presse Medicale (Paris, France : 1983)|October 2, 2001
[What is new on transplantation in 2001?]E Thervet
Nephrologie|December 26, 2002
[Role of the CESAR protocol: treatment of visceral Henoch-Schonlein purpura]E Thervet
Presse Medicale (Paris, France : 1983)|October 2, 2001
[Minimization of immunosuppression]E Thervet
Pathologie-Biologie|March 27, 2001
[Mycophenolate mofetil: a new approach by immunosuppressive treatment]E Thervet
Transplantation Proceedings|March 15, 2000
Cytomegalovirus prophylaxis in solid organ transplant recipients: the issuesC Legendre, E Thervet
Transplantation Proceedings|June 24, 1998
Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantationB Charpentier, E Thervet
Pathologie-Biologie|November 26, 1999
[New immunosuppressive agents]G Socié, E Thervet
Lancet (London, England)|January 9, 2003
Outcome after childhood Henoch-Schönlein purpuraE Thervet, E Pillebout, Loïc Guillevin, et al.
Nephrologie|January 31, 2002
[Pharmacology of mycophenolate mofetil: recent data and clinical consequences]E Thervet, D Anglicheau, C Legendre
Diabetes & Metabolism|May 17, 2001
[New immunosuppressive drugs and diabetes]C Legendre, E Thervet, J Bédrossian
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Presse Medicale (Paris, France : 1983)|October 2, 2001
[What is new on transplantation in 2001?]E Thervet
Nephrologie|December 26, 2002
[Role of the CESAR protocol: treatment of visceral Henoch-Schonlein purpura]E Thervet
Presse Medicale (Paris, France : 1983)|October 2, 2001
[Minimization of immunosuppression]E Thervet
Pathologie-Biologie|March 27, 2001
[Mycophenolate mofetil: a new approach by immunosuppressive treatment]E Thervet
Transplantation Proceedings|March 15, 2000
Cytomegalovirus prophylaxis in solid organ transplant recipients: the issuesC Legendre, E Thervet
Transplantation Proceedings|June 24, 1998
Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantationB Charpentier, E Thervet
Pathologie-Biologie|November 26, 1999
[New immunosuppressive agents]G Socié, E Thervet
Lancet (London, England)|January 9, 2003
Outcome after childhood Henoch-Schönlein purpuraE Thervet, E Pillebout, Loïc Guillevin, et al.
Nephrologie|January 31, 2002
[Pharmacology of mycophenolate mofetil: recent data and clinical consequences]E Thervet, D Anglicheau, C Legendre
Diabetes & Metabolism|May 17, 2001
[New immunosuppressive drugs and diabetes]C Legendre, E Thervet, J Bédrossian
Pageof 11